VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$99.9M
1-Year Return
37.46%
This Quarter Return
+15.01%
1 Year Return
+37.46%
3 Year Return
+659.14%
5 Year Return
–
10 Year Return
–
AUM
$99.9M
AUM Growth
+$2.74M
(+2.8%)
Cap. Flow
-$2.31M
Cap. Flow
% of AUM
-2.32%
Top 10 Holdings %
Top 10 Hldgs %
70.22%
Holding
57
New
9
Increased
16
Reduced
5
Closed
7
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
+$4.87M |
| 2 |
ALMS
Alumis Inc. Common Stock
ALMS
|
+$4.86M |
| 3 |
Arvinas
ARVN
|
+$3.68M |
| 4 |
Rezolute
RZLT
|
+$1.56M |
| 5 |
Sutro Biopharma
STRO
|
+$1.45M |
Top Sells
| 1 |
SLRN
ACELYRIN
SLRN
|
+$8.32M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$8.19M |
| 3 |
Praxis Precision Medicines
PRAX
|
+$1.5M |
| 4 |
Instil Bio
TIL
|
+$1.2M |
| 5 |
Immunome
IMNM
|
+$1.03M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Heron Therapeutics
HRTX
$193M
| $14.5M | 14.29% |
6,986,744
| – | – |
|
|
VRNA
2
Verona Pharma
VRNA
$9.21B
| $8.99M | 8.88% |
95,000
| – | – |
|
3
Jasper Therapeutics
JSPR
$39.5M
| $7.96M | 7.86% |
1,433,828
| – | – |
|
4
Protara Therapeutics
TARA
$121M
| $6.48M | 6.4% |
2,139,000
+471,200
| +28% | +$1.43M |
|
5
Zevra Therapeutics
ZVRA
$435M
| $6.3M | 6.22% |
715,000
+50,000
| +8% | +$441K |
|
6
Tourmaline Bio
TRML
$1.22B
| $6.3M | 6.22% |
393,889
-61,523
| -14% | -$984K |
|
|
7
Praxis Precision Medicines
PRAX
$794M
| $6.28M | 6.2% |
149,334
-35,666
| -19% | -$1.5M |
|
|
8
Cidara Therapeutics
CDTX
$1.66B
| $4.87M | 4.81% |
+100,000
| New | +$4.87M |
|
|
ALMS
9
Alumis Inc. Common Stock
ALMS
$455M
| $4.86M | 4.8% |
+1,620,846
| New | +$4.86M |
|
|
10
Arvinas
ARVN
$568M
| $3.68M | 3.64% |
+500,000
| New | +$3.68M |
|
11
scPharmaceuticals
SCPH
$302M
| $3.5M | 3.45% |
917,668
| – | – |
|
|
12
Rezolute
RZLT
$669M
| $3.35M | 3.3% |
750,000
+350,000
| +88% | +$1.56M |
|
13
Liquidia Corp
LQDA
$2.24B
| $2.98M | 2.94% |
239,260
-60,740
| -20% | -$757K |
|
14
Mineralys Therapeutics
MLYS
$2.88B
| $2.36M | 2.33% |
174,600
+24,000
| +16% | +$325K |
|
|
15
Sutro Biopharma
STRO
$74.3M
| $2.18M | 2.16% |
3,060,000
+2,030,000
| +197% | +$1.45M |
|
16
InspireMD
NSPR
$99.3M
| $2.05M | 2.03% |
904,029
| – | – |
|
17
Perspective Therapeutics
CATX
$258M
| $1.72M | 1.7% |
500,000
| – | – |
|
18
Replimune Group
REPL
$447M
| $1.7M | 1.68% |
183,083
+1,000
| +0.5% | +$9.29K |
|
19
TELA Bio
TELA
$62.6M
| $1.45M | 1.43% |
747,410
| – | – |
|
20
Edesa Biotech
EDSA
$16.9M
| $1.4M | 1.38% |
687,500
| – | – |
|
21
Viridian Therapeutics
VRDN
$1.54B
| $1.21M | 1.19% |
+86,500
| New | +$1.21M |
|
|
UPB
22
Upstream Bio, Inc. Common Stock
UPB
$947M
| $1.17M | 1.16% |
107,000
| – | – |
|
23
Eledon Pharmaceuticals
ELDN
$145M
| $919K | 0.91% |
338,973
+15,000
| +5% | +$40.7K |
|
24
Avalo Therapeutics
AVTX
$140M
| $773K | 0.76% |
154,972
+43,000
| +38% | +$215K |
|
25
Tenax Therapeutics
TENX
$27.9M
| $480K | 0.47% |
83,333
| – | – |
|